Asthma and COPD patients needed for research working group

Asthma and COPD patients needed to join a working group for EU project.

We are looking for people with asthma or COPD to join a working group to advise researchers on a new project called 3TR. This project, which was launched in October 2019, will help us to understand why some patients’ symptoms improve with certain treatments while other patients continue to experience severe symptoms.

3TR will explore seven different immune-mediated, allergic and inflammatory diseases, including: asthma, COPD, Crohn’s disease, ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.

The information that we gain from this study will lead to improved asthma and COPD management and personalised therapy. This will be achieved by being able to better predict whether or not a patient will benefit from a specific treatment.

The European Lung Foundation (ELF) and the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), are partners on this project and are setting up a patient working group. This working group will provide advice to researchers and ensure that patients are at the centre of the project activities, for example: asthma and COPD patient priorities, data collection, research design and communicating information about the research to the public.

If you have experience of either asthma or COPD and are interested in improving treatment for other people affected by these conditions, then please contact us before Monday 24 February 2020; you can do this via email:

Related links

3TR Website





This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 831434 (3TR). The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Disclaimer: Content of this publication reflects only the author’s view and the JU is not responsible for any use that may be made of the information it contains.